Does NIRAPARIB Cause Recurrent cancer? 776 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 776 reports of Recurrent cancer have been filed in association with NIRAPARIB (ZEJULA). This represents 3.6% of all adverse event reports for NIRAPARIB.
776
Reports of Recurrent cancer with NIRAPARIB
3.6%
of all NIRAPARIB reports
5
Deaths
115
Hospitalizations
How Dangerous Is Recurrent cancer From NIRAPARIB?
Of the 776 reports, 5 (0.6%) resulted in death, 115 (14.8%) required hospitalization, and 9 (1.2%) were considered life-threatening.
Is Recurrent cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIRAPARIB. However, 776 reports have been filed with the FAERS database.
What Other Side Effects Does NIRAPARIB Cause?
Nausea (5,794)
Fatigue (5,240)
Constipation (4,128)
Platelet count decreased (4,102)
Insomnia (2,861)
Blood pressure increased (2,464)
Headache (2,383)
Off label use (2,213)
Vomiting (2,029)
Carbohydrate antigen 125 increased (1,868)
What Other Drugs Cause Recurrent cancer?
IMATINIB (237)
CYCLOPHOSPHAMIDE (143)
TRASTUZUMAB (121)
CAPECITABINE (108)
PEMBROLIZUMAB (107)
RITUXIMAB (99)
DOXORUBICIN (97)
OCTREOTIDE (95)
METHOTREXATE (81)
OLAPARIB (77)
Which NIRAPARIB Alternatives Have Lower Recurrent cancer Risk?
NIRAPARIB vs NIRMATRELVIR\RITONAVIR
NIRAPARIB vs NIROGACESTAT
NIRAPARIB vs NIROGACESTAT HYDROBROMIDE
NIRAPARIB vs NIRSEVIMAB
NIRAPARIB vs NIRSEVIMAB-ALIP